ArticleHead and neck pathology2025
NUT Carcinoma of the Head and Neck: Clinicopathologic and Molecular Analysis of 18 Cases.
Article in Head and neck pathology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Several Considerations on the Pathology, Treatment, and Prognosis of Laryngeal NUT Carcinoma.Oncology and therapy · 2026Article
- Leptomeningeal carcinomatosis in sinonasal NUT carcinoma: a case report and review of intracranial involvement.Frontiers in oncology · 2026Article
- Sequential multimodal management for recurrent pulmonary NUT carcinoma: a case report.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
purposeNUT carcinoma (NC) is a rare, aggressive neoplasm with limited therapeutic options. This study aimed to delineate the clinicopathologic and molecular characteristics of head and neck NC (HNNC) to refine diagnostic strategies and identify prognostic factors. METHODS AND
resultsWe conducted a retrospective analysis of 18 HNNC cases from a single institution (2015-2024). Our cohort consisted of 7 males and 11 females, aged 14-72 years (mean: 45 years), with the predominant site of involvement being the sinonasal tract (77.8%), followed by the larynx (16.7%) and the nasopharynx (5.5%). Microscopically, HNNCs typically grew as nests and sheets of poorly differentiated cells with focal or extensive abrupt keratinization. Several cases also displayed distinct morphological variants, including spindle cell components (4/18), basaloid (1/18), ameloblastic-like (1/18), papillary structures (1/18), monomorphic cell clusters (1/18), and concentric pattern around blood vessels (2/18). All cases were moderately to strongly positive for NUT protein (H-score: 80 to 300). PD-L1 was expressed in 43.8% of tumors (7/16). FISH confirmed NUTM1 rearrangement in 15 cases (15/16, 93.8%), and RNA sequencing analysis of 14 cases revealed the following fusion patterns: NUTM1::BRD4 (10/14, 71.4%), NUTM1::BRD3 (3/14, 21.4%), and NUTM1::NSD3 (1/14, 7.1%). Follow-up data were available for 17 patients (range: 2-52 months), among whom 10 patients died of the disease. The median overall survival was 12 months.
conclusionsThis large single-center series confirms that HNNC exhibits marked morphological heterogeneity and poor prognosis. Accurate diagnosis relies on immunohistochemistry, with FISH and RNA sequencing as needed, offering molecular insights to guide prognosis and clinical management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.